Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Coley WB. The treatment of malignant tumors by repeated inoculationsof erysipelas. With a report of ten original cases. Am J Med Sci 1893; 105: 487–511.
Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: movingbeyond current vaccines. Nat Med 2004; 10: 909–915.
Tang DC, DeVit M, Johnston SA. Genetic immunization is a simplemethod for eliciting an immune response. Nature 1992; 356: 152–154.
Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protectionagainst influenza by injection of DNA encoding a viral protein. Science 1993; 259: 1745–1749.
Fynan EF, Webster RG, Fuller DH et al. DNA vaccines: protectiveimmunizations by parenteral, mucosal, and gene-gun inoculations. Proc Natl Acad Sci U S A 1993; 90: 1147811482..
Wang B, Ugen KE, Srikantan V et al. Gene inoculation generatesimmune responses against human immunodeficiency virus type 1. ProcNatl Acad Sci U S A 1993; 90: 4156–4160.
Davis HL, Michel ML, Mancini M et al. Direct gene transfer inskeletal muscle: plasmid DNA-based immunization against thehepatitis B virus surface antigen. Vaccine 1994; 12: 15031509..
Wang R, Doolan DL, Le TP et al. Induction of antigen-specificcytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998; 282: 476–480.
MacGregor RR, Boyer JD, Ugen KE et al. First human trial of aDNA-based vaccine for treatment of human immunodeficiency virus type1 infection: safety and host response. J Infect Dis 1998; 178:92–100.
Rottinghaus ST, Poland GA, Jacobson RM et al. Hepatitis B DNAvaccine induces protective antibody responses in humannon-responders to conventional vaccination. Vaccine 2003; 21:4604–4608.
Casares S, Inaba K, Brumeanu TD et al. Antigen presentation bydendritic cells after immunization with DNA encoding a majorhistocompatibility complex class II-restricted viral epitope. J ExpMed 1997; 186: 1481–1486.
Corr M, von Damm A, Lee DJ, Tighe H. In vivo priming by DNAinjection occurs predominantly by antigen transfer. J Immunol 1999;163: 4721–4727.
Porgador A, Irvine KR, Iwasaki A et al. Predominant role fordirectly transfected dendritic cells in antigen presentation to CD8+T cells after gene gun immunization. J Exp Med 1998; 188:1075–1082.
14. Akbari O, Panjwani N, Garcia S et al. DNA vaccination:transfection and activation of dendritic cells as key events forimmunity. J Exp Med 1999; 189: 169–178.
Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA triggerdirect B-cell activation. Nature 1995; 374: 546–549.
Sato Y, Roman M, Tighe H et al. Immunostimulatory DNA sequencesnecessary for effective intradermal gene immunization. Science 1996;273: 352–354.
Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizesbacterial DNA. Nature 2000; 408: 740–745.
Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helpercell types and antibody isotypes generated by saline and gene gunDNA immunization. J Immunol 1997; 158: 2278–2284.
Pertmer TM, Roberts TR, Haynes JR. Influenza virusnucleoprotein-specific immunoglobulin G subclass and cytokineresponses elicited by DNA vaccination are dependent on the route ofvector DNA delivery. J Virol 1996; 70: 6119–6125.
Turk MJ, Wolchok JD, Guevara-Patino JA et al. Multiple pathways totumor immunity and concomitant autoimmunity. Immunol Rev 2002; 188:122–135.
Wlazlo AP, Deng H, Giles-Davis W, Ertl HC. DNA vaccines against thehuman papillomavirus type 16 E6 or E7 oncoproteins. Cancer Gene Ther2004; 11: 457–464.
Wolfel T, Hauer M, Schneider J et al. A p16INK4a-insensitive CDK4mutant targeted by cytolytic T lymphocytes in a human melanoma.Science 1995; 269: 1281–1284.
Robbins PF, El-Gamil M, Li YF et al. A mutated beta-catenin geneencodes a melanoma-specific antigen recognized by tumor infiltratinglymphocytes. J Exp Med 1996; 183: 1185–1192.
Pinilla-Ibarz J, Cathcart K, Korontsvit T et al. Vaccination ofpatients with chronic myelogenous leukemia with bcr-abl oncogenebreakpoint fusion peptides generates specific immune responses. Blood 2000; 95: 1781–1787.
Scanlan MJ, Gure AO, Jungbluth AA et al. Cancer/testis antigens: anexpanding family of targets for cancer immunotherapy. Immunol Rev2002; 188: 22–32.
O’Garra A, Vieira P. Regulatory T cells and mechanisms of immunesystem control. Nat Med 2004; 10: 801–805.
Brichard V, Van Pel A, Wolfel T et al. The tyrosinase gene codes foran antigen recognized by autologous cytolytic T lymphocytes onHLA-A2 melanomas. J Exp Med 1993; 178: 489–495.
Wang RF, Appella E, Kawakami Y et al. Identification of TRP-2 as ahuman tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med1996; 184: 2207–2216.
Bakker AB, Schreurs MW, de Boer AJ et al. Melanocytelineage-specific antigen gp100 is recognized by melanoma-derivedtumor-infiltrating lymphocytes. J Exp Med 1994; 179: 10051009..
Kawakami Y, Eliyahu S, Delgado CH et al. Cloning of the gene codingfor a shared human melanoma antigen recognized by autologous T cellsinfiltrating into tumor. Proc Natl Acad Sci U S A 1994; 91:3515–3519.
Vijayasaradhi S, Bouchard B, Houghton AN. The melanoma antigen gp75is the human homologue of the mouse b (brown) locus gene product. JExp Med 1990; 171: 1375–1380.
Naftzger C, Takechi Y, Kohda H et al. Immune response to adifferentiation antigen induced by altered antigen: a study of tumorrejection and autoimmunity. Proc Natl Acad Sci U S A 1996; 93:14809–14814.
Weber LW, Bowne WB, Wolchok JD et al. Tumor immunity andautoimmunity induced by immunization with homologous DNA. J ClinInvest 1998; 102: 1258–1264.
Bowne WB, Srinivasan R, Wolchok JD et al. Coupling and uncoupling oftumor immunity and autoimmunity. J Exp Med 1999; 190: 1717–1722.
Hawkins WG, Gold JS, Dyall R et al. Immunization with DNA coding forgp100 results in CD4 T-cell independent antitumor immunity. Surgery2000; 128: 273–280.
Steitz J, Bruck J, Steinbrink K et al. Genetic immunization of micewith human tyrosinase-related protein 2: implications for theimmunotherapy of melanoma. Int J Cancer 2000; 86: 89–94.
Rakhmilevich AL, Imboden M, Hao Z et al. Effective particle-mediatedvaccination against mouse melanoma by coadministration of plasmidDNA encoding Gp100 and granulocyte-macrophage colony-stimulatingfactor. Clin Cancer Res 2001; 7: 952–961.
Schreurs MW, de Boer AJ, Figdor CG, Adema GJ. Genetic vaccinationagainst the melanocyte lineage-specific antigen gp100 inducescytotoxic T lymphocyte-mediated tumor protection. Cancer Res 1998;58: 2509–2514.
Bergman PJ, McKnight J, Novosad A et al. Long-term survival of dogswith advanced malignant melanoma after DNA vaccination withxenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003;9: 1284–1290.
Gold JS, Ferrone CR, Guevara-Patino JA et al. A single heterocliticepitope determines cancer immunity after xenogeneic DNA immunizationagainst a tumor differentiation antigen. J Immunol 2003; 170:5188–5194.
Marshall J. Carcinoembryonic antigen-based vaccines. Semin Oncol2003; 30: 30–36.
Conry RM, LoBuglio AF, Loechel F et al. A carcinoembryonic antigenpolynucleotide vaccine has in vivo antitumor activity. Gene Ther1995; 2: 59–65.
Niethammer AG, Primus FJ, Xiang R et al. An oral DNA vaccine againsthuman carcinoembryonic antigen (CEA) prevents growth anddissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine 2001; 20: 421–429.
Zhou H, Luo Y, Mizutani M et al. A novel transgenic mouse model forimmunological evaluation of carcinoembryonic antigen-based DNAminigene vaccines. J Clin Invest 2004; 113: 1792–1798.
Disis ML, Calenoff E, McLaughlin G et al. Existent T-cell andantibody immunity to HER-2/neu protein in patients with breastcancer. Cancer Res 1994; 54: 16–20.
Peoples GE, Goedegebuure PS, Smith R et al. Breast and ovariancancer-specific cytotoxic T lymphocytes recognize the sameHER2/neu-derived peptide. Proc Natl Acad Sci U S A 1995; 92:432–436.
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus amonoclonal antibody against HER2 for metastatic breast cancer thatoverexpresses HER2. N Engl J Med 2001; 344: 783–792.
Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety oftrastuzumab as a single agent in first-line treatment ofHER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719–726.
Chen Y, Hu D, Eling DJ et al. DNA vaccines encoding full-length ortruncated Neu induce protective immunity against Neu-expressingmammary tumors. Cancer Res 1998; 58: 1965–1971.
Piechocki MP, Pilon SA, Wei WZ. Complementary antitumor immunityinduced by plasmid DNA encoding secreted and cytoplasmic humanErbB-2. J Immunol 2001; 167: 33673374..
Foy TM, Bannink J, Sutherland RA et al. Vaccination with Her-2/neuDNA or protein subunits protects against growth of aHer-2/neu-expressing murine tumor. Vaccine 2001; 19: 2598–2606.
Amici A, Venanzi FM, Concetti A. Genetic immunization againstneu/erbB2 transgenic breast cancer. Cancer Immunol Immunother 1998;47: 183–190.
Quaglino E, Iezzi M, Mastini C et al. Electroporated DNA vaccineclears away multifocal mammary carcinomas in her-2/neu transgenicmice. Cancer Res 2004; 64: 2858–2864.
Spadaro M, Ambrosino E, Iezzi M et al. Cure of mammary carcinomas inHer-2 transgenic mice through sequential stimulation of innate(neoadjuvant interleukin-12) and adaptive (DNA vaccineelectroporation) immunity. Clin Cancer Res 2005; 11: 1941–1952.
Syrengelas AD, Chen TT, Levy R. DNA immunization induces protectiveimmunity against B-cell lymphoma. Nat Med 1996; 2: 1038–1041.
King CA, Spellerberg MB, Zhu D et al. DNA vaccines with single-chainFv fused to fragment C of tetanus toxin induce protective immunityagainst lymphoma and myeloma. Nat Med 1998; 4: 1281–1286.
Stevenson FK, Ottensmeier CH, Johnson P et al. DNA vaccines toattack cancer. Proc Natl Acad Sci U S A 2004; 101 Suppl 2:14646–14652.
Thirdborough SM, Radcliffe JN, Friedmann PS, Stevenson FK. Vaccination with DNA encoding a single-chain TCR fusion proteininduces anticlonotypic immunity and protects against T-celllymphoma. Cancer Res 2002; 62: 1757–1760.
Palomba ML, Roberts WK, Dao T et al. CD8+ T-cell-dependent immunityfollowing xenogeneic DNA immunization against CD20 in a tumorchallenge model of B-cell lymphoma. Clin Cancer Res 2005; 11:370–379.
Padua RA, Larghero J, Robin M et al. PML-RARA-targeted DNA vaccineinduces protective immunity in a mouse model of leukemia. Nat Med2003; 9: 1413–1417.
Johnen H, Kulbe H, Pecher G. Long-term tumor growth suppression inmice immunized with naked DNA of the human tumor antigen mucin(MUC1). Cancer Immunol Immunother 2001; 50: 356–360.
Kontani K, Taguchi O, Ozaki Y et al. Novel vaccination protocolconsisting of injecting MUC1 DNA and nonprimed dendritic cells atthe same region greatly enhanced MUC1-specific antitumor immunity ina murine model. Cancer Gene Ther 2002; 9: 330–337.
Rosenberg SA, Yang JC, Sherry RM et al. Inability to ImmunizePatients with Metastatic Melanoma Using Plasmid DNA Encoding thegp100 Melanoma-Melanocyte Antigen. Hum Gene Ther 2003; 14: 709–714.
Tagawa ST, Lee P, Snively J et al. Phase I study of intranodaldelivery of a plasmid DNA vaccine for patients with Stage IVmelanoma. Cancer 2003; 98: 144–154.
Triozzi PL, Aldrich W, Allen KO et al. Phase I study of a plasmidDNA vaccine encoding MART-1 in patients with resected melanoma atrisk for relapse. J Immunother 2005; 28: 382–388.
Mincheff M, Tchakarov S, Zoubak S et al. Naked DNA and adenoviralimmunizations for immunotherapy of prostate cancer: a phase I/IIclinical trial. Eur Urol 2000; 38: 208–217.
Pavlenko M, Roos AK, Lundqvist A et al. A phase I trial of DNAvaccination with a plasmid expressing prostate-specific antigen inpatients with hormone-refractory prostate cancer. Br J Cancer 2004;91: 688–694.
Miller AM, Ozenci V, Kiessling R, Pisa P. Immune monitoring in aphase 1 trial of a PSA DNA vaccine in patients withhormone-refractory prostate cancer. J Immunother 2005; 28: 389–395.
Timmerman JM, Singh G, Hermanson G et al. Immunogenicity of aplasmid DNA vaccine encoding chimeric idiotype in patients withB-cell lymphoma. Cancer Res 2002; 62: 5845–5852.
Conry RM, Curiel DT, Strong TV et al. Safety and immunogenicity of aDNA vaccine encoding carcinoembryonic antigen and hepatitis Bsurface antigen in colorectal carcinoma patients. Clin Cancer Res2002; 8: 2782–2787.
Smith CL, Dunbar PR, Mirza F et al. Recombinant modified vacciniaAnkara primes functionally activated CTL specific for a melanomatumor antigen epitope in melanoma patients with a high risk ofdisease recurrence. Int J Cancer 2005; 113: 259–266.
Kadowaki N, Ho S, Antonenko S et al. Subsets of human dendritic cellprecursors express different toll-like receptors and respond todifferent microbial antigens. J Exp Med 2001; 194: 863–869.
Hochrein H, O’Keeffe M, Wagner H. Human and mouse plasmacytoiddendritic cells. Hum Immunol 2002; 63: 1103–1110.
Zou W. Immunosuppressive networks in the tumour environment andtheir therapeutic relevance. Nat Rev Cancer 2005; 5: 263–274.
Toka FN, Pack CD, Rouse BT. Molecular adjuvants for mucosalimmunity. Immunol Rev 2004; 199: 100–112.
Calarota SA, Weiner DB. Enhancement of human immunodeficiency virustype 1-DNA vaccine potency through incorporation of T-helper 1molecular adjuvants. Immunol Rev 2004; 199: 84–99.
Prud’homme GJ. DNA vaccination against tumors. J Gene Med 2005; 7:3–17.
Cohen AD, Boyer JD, Weiner DB. Modulating the immune response togenetic immunization. Faseb J 1998; 12: 1611–1626.
Barouch DH, Santra S, Schmitz JE et al. Control of viremia andprevention of clinical AIDS in rhesus monkeys by cytokine-augmentedDNA vaccination. Science 2000; 290: 486–492.
Ferrone CR, Perales M-A, Somberg CJ et al. Enhancement of CD8 T-cellresponses and tumor protection following xenogeneic DNA immunizationagainst a tumor antigen with IL-12/Ig DNA and IL-15/Ig DNA.Submitted for publication.
Barouch DH, Truitt DM, Letvin NL. Expression kinetics of theinterleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. Vaccine 2004; 22: 3092–3097.
Bowne WB, Wolchok JD, Hawkins WG et al. Injection of DNA encodinggranulocyte-macrophage colony-stimulating factor recruits dendriticcells for immune adjuvant effects. Cytokines Cell Mol Ther 1999; 5:217–225.
Perales MA, Fantuzzi G, Goldberg SM et al. GM-CSF DNA inducesspecific patterns of cytokines and chemokines in the skin:implications for DNA vaccines. Cytokines Cell Mol Ther 2002; 7:125–133.
Chow YH, Chiang BL, Lee YL et al. Development of Th1 and Th2populations and the nature of immune responses to hepatitis B virusDNA vaccines can be modulated by codelivery of various cytokinegenes. J Immunol 1998; 160: 1320–1329.
Bertley FM, Kozlowski PA, Wang SW et al. Control of simian/humanimmunodeficiency virus viremia and disease progression afterIL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccinationin nonhuman primates. J Immunol 2004; 172: 3745–3757.
Weiss WR, Ishii KJ, Hedstrom RC et al. A plasmid encoding murinegranulocyte-macrophage colony-stimulating factor increasesprotection conferred by a malaria DNA vaccine. J Immunol 1998; 161:2325–2332.
Sin JI, Kim JJ, Arnold RL et al. IL-12 gene as a DNA vaccineadjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ Tcell-mediated protective immunity against herpes simplex virus-2challenge. J Immunol 1999; 162: 2912–2921.
Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of antigen andgenetic adjuvants on immune responses to human immunodeficiencyvirus DNA vaccines in mice. J Virol 2002; 76: 243–250.
Kim JJ, Yang JS, Dang K et al. Engineering enhancement of immuneresponses to DNA-based vaccines in a prostate cancer model in rhesusmacaques through the use of cytokine gene adjuvants. Clin Cancer Res2001; 7: 882.s-889s.
Geissler M, Gesien A, Tokushige K, Wands JR. Enhancement of cellularand humoral immune responses to hepatitis C virus core protein usingDNA-based vaccines augmented with cytokine-expressing plasmids. JImmunol 1997; 158: 1231–1237.
Kim JJ, Nottingham LK, Tsai A et al. Antigen-specific humoral andcellular immune responses can be modulated in rhesus macaquesthrough the use of IFN-gamma, IL-12, or IL-18 gene adjuvants. J MedPrimatol 1999; 28: 214–223.
Conry RM, Widera G, LoBuglio AF et al. Selected strategies toaugment polynucleotide immunization. Gene Ther 1996; 3: 67–74.
Kutzler MA, Robinson TM, Chattergoon MA et al. Coimmunization withan optimized IL-15 plasmid results in enhanced function andlongevity of CD8 T cells that are partially independent of CD4 Tcell help. J Immunol 2005; 175: 112–123.
Billaut-Mulot O, Idziorek T, Loyens M et al. Modulation of cellularand humoral immune responses to a multiepitopic HIV-1 DNA vaccine byinterleukin-18 DNA immunization/viral protein boost. Vaccine 2001;19: 2803–2811.
Zhu M, Xu X, Liu H et al. Enhancement of DNA vaccine potency againstherpes simplex virus 1 by co-administration of an interleukin-18expression plasmid as a genetic adjuvant. J Med Microbiol 2003; 52:223–228.
Hung CF, Hsu KF, Cheng WF et al. Enhancement of DNA vaccine potencyby linkage of antigen gene to a gene encoding the extracellulardomain of Fms-like tyrosine kinase 3-ligand. Cancer Res 2001; 61:1080–1088.
Sailaja G, Husain S, Nayak BP, Jabbar AM. Long-term maintenance ofgp120-specific immune responses by genetic vaccination with theHIV-1 envelope genes linked to the gene encoding Flt-3 ligand. JImmunol 2003; 170: 2496–2507.
Sang H, Pisarev VM, Munger C et al. Regional, but not systemicrecruitment/expansion of dendritic cells by a pluronic-formulatedFlt3-ligand plasmid with vaccine adjuvant activity. Vaccine 2003;21: 3019–3029.
Sumida SM, McKay PF, Truitt DM et al. Recruitment and expansion ofdendritic cells in vivo potentiate the immunogenicity of plasmid DNAvaccines. J Clin Invest 2004; 114: 13341342..
Zlotnik A, Yoshie O. Chemokines: a new classification system andtheir role in immunity. Immunity 2000; 12: 121–127.
Kim JJ, Nottingham LK, Sin JI et al. CD8 positive T cells influenceantigen-specific immune responses through the expression ofchemokines. J Clin Invest 1998;
1112–1124. 102. Lu Y, Xin KQ, Hamajima K et al. Macrophageinflammatory protein-1alpha (MIP1alpha) expression plasmid enhancesDNA vaccine-induced immune response against HIV-1. Clin Exp Immunol1999; 115: 335–341.
Pinto AR, Reyes-Sandoval A, Ertl HC. Chemokines and TRANCE asgenetic adjuvants for a DNA vaccine to rabies virus. Cell Immunol2003; 224: 106–113.
Sin J, Kim JJ, Pachuk C et al. DNA vaccines encoding interleukin-8and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediatedprotective immunity against herpes simplex virus type 2 in vivo. JVirol 2000; 74: 11173–11180.
Eo SK, Lee S, Chun S, Rouse BT. Modulation of immunity againstherpes simplex virus infection via mucosal genetic transfer ofplasmid DNA encoding chemokines. J Virol 2001; 75: 569–578.
Eo SK, Lee S, Kumaraguru U, Rouse BT. Immunopotentiation of DNAvaccine against herpes simplex virus via co-delivery of plasmid DNAexpressing CCR7 ligands. Vaccine 2001; 19: 4685–4693.
Xiang R, Mizutani N, Luo Y et al. A DNA vaccine targeting survivincombines apoptosis with suppression of angiogenesis in lung tumoreradication. Cancer Res 2005; 65: 553–561.
Youssef S, Maor G, Wildbaum G et al. C-C chemokine-encoding DNAvaccines enhance breakdown of tolerance to their gene products andtreat ongoing adjuvant arthritis. J Clin Invest 2000; 106: 361–371.
Kim JJ, Bagarazzi ML, Trivedi N et al. Engineering of in vivo immuneresponses toDNA immunization via codelivery of costimulatory molecule genes. NatBiotechnol 1997; 15: 641–646.
Iwasaki A, Stiernholm BJ, Chan AK et al. Enhanced CTL responsesmediated by plasmid DNA immunogens encoding costimulatory moleculesand cytokines. J Immunol 1997; 158: 4591–4601.
Schoenberger SP, Toes RE, van der Voort EI et al. T-cell help forcytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480–483.
Bennett SR, Carbone FR, Karamalis F et al. Help for cytotoxic-T-cellresponses is mediated by CD40 signalling. Nature 1998; 393:478–480.
Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell canbe a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474–478.
Mendoza RB, Cantwell MJ, Kipps TJ. Immunostimulatory effects of aplasmid expressing CD40 ligand (CD154) on gene immunization. JImmunol 1997; 159: 5777–5781.
Xiang R, Primus FJ, Ruehlmann JM et al. A dual-function DNA vaccineencoding carcinoembryonic antigen and CD40 ligand trimer induces Tcell-mediated protective immunity against colon cancer incarcinoembryonic antigen-transgenic mice. J Immunol 2001; 167:4560–4565.
Sin JI, Kim JJ, Zhang D, Weiner DB. Modulation of cellular responsesby plasmid CD40L plasmid vectors enhance antigen-specific helper T cell type 1CD4+ T cell-mediated protective immunity against herpes simplexvirus type 2 in vivo. Hum Gene Ther 2001;12: 1091–1102.
117. Hung CF, Cheng WF, Chai CY et al. Improving vaccine potencythrough intercellular spreading and enhanced MHC class Ipresentation of antigen. J Immunol 2001; 166: 5733–5740.
Hung CF, Cheng WF, Hsu KF et al. Cancer immunotherapy using a DNAvaccine encoding the translocation domain of a bacterial toxinlinked to a tumor antigen. Cancer Res 2001; 61: 3698–3703.
Rohrbach F, Weth R, Kursar M et al. Targeted delivery of theErbB2/HER2 tumor antigen to professional APCs results in effectiveantitumor immunity. J Immunol 2005; 174: 5481–5489.
Leitner WW, Hwang LN, deVeer MJ et al. Alphavirus-based DNA vaccinebreaks immunological tolerance by activating innate antiviralpathways. Nat Med 2003; 9: 33–39.
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition ofdouble-stranded RNA and activation of NF-kappaB by Toll-likereceptor 3. Nature 2001; 413: 732–738.
Xiang R, Lode HN, Chao TH et al. An autologous oral DNA vaccineprotects against murine melanoma. Proc Natl Acad Sci U S A 2000; 97:5492–5497.
Woo PC, Wong LP, Zheng BJ, Yuen KY. Unique immunogenicity ofhepatitis B virus DNA vaccine presented by live-attenuatedSalmonella typhimurium. Vaccine 2001; 19: 29452954..
Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into itsbiological function and use in tumor immunotherapy. Nat Immunol2002; 3: 611–618.
van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy ofB16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4(CTLA-4) and granulocyte/macrophage colony-stimulating factor(GM-CSF)-producing vaccines induces rejection of subcutaneous andmetastatic tumors accompanied by autoimmune depigmentation. J ExpMed 1999; 190: 355–366.
Phan GQ, Yang JC, Sherry RM et al. Cancer regression andautoimmunity induced by cytotoxic T lymphocyte-associated antigen 4blockade in patients with metastatic melanoma. Proc Natl Acad Sci US A 2003; 100: 8372–8377.
Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic Tlymphocyte-associated antigen 4 antibody blockade in previouslyvaccinated metastatic melanoma and ovarian carcinoma patients. ProcNatl Acad Sci U S A 2003; 100: 4712–4717.
Attia P, Phan GQ, Maker AV et al. Autoimmunity Correlates With TumorRegression in Patients With Metastatic Melanoma Treated WithAnti-Cytotoxic T-Lymphocyte Antigen-4.break J Clin Oncol 2005.
Gregor PD, Wolchok JD, Turaga V et al. Induction of autoantibodiesto syngeneic prostate-specific membrane antigen by xenogeneicvaccination. Int J Cancer 2005; 116: 415–421.
Nocentini G, Riccardi C. GITR: a multifaceted regulator of immunitybelonging to the tumor necrosis factor receptor superfamily. Eur JImmunol 2005; 35: 1016–1022.
Shimizu J, Yamazaki S, Takahashi T et al. Stimulation ofCD25(+)CD4(+) regulatory T cells through GITR breaks immunologicalself-tolerance. Nat Immunol 2002; 3: 135–142.
McHugh RS, Whitters MJ, Piccirillo CA et al. CD4(+)CD25(+)immunoregulatory T cells: gene expression analysis reveals afunctional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16: 311–323.
Ko K, Yamazaki S, Nakamura K et al. Treatment of advanced tumorswith agonistic anti-GITR mAb and its effects on tumor-infiltratingFoxp3+CD25+CD4+ regulatory T cells. J Exp Med 2005; 202: 885–891.
Cohen AD, Diab A, Perales M-A et al. Agonist anti-GITR antibodyenhances DNA vaccine-induced CD8+ T cell responses and tumorimmunity against melanoma. Submitted for publication.
Sun JY, Krouse RS, Forman SJ et al. Immunogenicity of ap210(BCR-ABL) fusion domain candidate DNA vaccine targeted todendritic cells by a recombinant adeno-associated virus vector invitro. Cancer Res 2002; 62: 3175–3183.
Park JH, Kim CJ, Lee JH et al. Effective immunotherapy of cancer byDNA vaccination. Mol Cells 1999; 9: 384–391.
Sypniewska RK, Hoflack L, Tarango M et al. Prevention of metastaseswith a Mage-b DNA vaccine in a mouse breast tumor model: potentialfor breast cancer therapy. Breast Cancer Res Treat 2005; 91: 19–28.
Hanke P, Serwe M, Dombrowski F et al. DNA vaccination withAFP-encoding plasmid DNA prevents growth of subcutaneousAFP-expressing tumors and does not interfere with liver regenerationin mice. Cancer Gene Ther 2002; 9: 346–355.
Meng WS, Butterfield LH, Ribas A et al. alpha-Fetoprotein-specifictumor immunity induced by plasmid prime-adenovirus boost geneticvaccination. Cancer Res 2001; 61: 8782–8786.
Tsuboi A, Oka Y, Ogawa H et al. Cytotoxic T-lymphocyte responseselicited to Wilms’tumor gene WT1 product by DNA vaccination. J ClinImmunol 2000; 20: 195–202.
Deng H, Kowalczyk D, O I et al. A modified DNA vaccine to p53induces protective immunity to challenge with a chemically inducedsarcoma cell line. Cell Immunol 2002; 215: 20–31.
Tuting T, Gambotto A, Robbins PD et al. Co-delivery of T helper1-biasing cytokine genes enhances the efficacy of gene gunimmunization of mice: studies with the model tumor antigenbeta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen. Gene Ther 1999; 6: 629–636.
Lindinger P, Mostbock S, Hammerl P et al. Induction of murine rasoncogene peptide-specific T cell responses by immunization withplasmid DNA-based minigene vectors. Vaccine 2003; 21: 4285–4296.
Bristol JA, Orsini C, Lindinger P et al. Identification of a rasoncogene peptide that contains both CD4(+) and CD8(+) T cellepitopes in a nested configuration and elicits both T cell subsetresponses by peptide or DNA immunization. Cell Immunol 2000; 205:73–83.
Kim JJ, Tsai A, Nottingham LK et al. Intracellular adhesionmolecule-1 modulates beta-chemokines and directly costimulates Tcells in vivo. J Clin Invest 1999; 103: 869–877.
Jeannin P, Renno T, Goetsch L et al. OmpA targets dendritic cells,induces their maturation and delivers antigen into the MHC class Ipresentation pathway. Nat Immunol 2000; 1: 502–509.
Chen CH, Wang TL, Hung CF et al. Enhancement of DNA vaccine potencyby linkage of antigen gene to an HSP70 gene. Cancer Res 2000; 60:1035–1042.
Otero M, Calarota SA, Felber B et al. Resiquimod is a modestadjuvant for HIV-1 gag-based genetic immunization in a mouse model.Vaccine 2004; 22: 1782–1790.
Zuber AK, Brave A, Engstrom G et al. Topical delivery of imiquimodto a mouse model as a novel adjuvant for human immunodeficiencyvirus (HIV) DNA. Vaccine 2004; 22: 1791–1798.
Thomsen LL, Topley P, Daly MG et al. Imiquimod and resiquimodin a mouse model: adjuvants for DNA vaccination by particle-mediatedimmunotherapeutic delivery. Vaccine 2004; 22: 1799–1809.
Niethammer AG, Xiang R, Becker JC et al. A DNA vaccine against VEGFreceptor 2 prevents effective angiogenesis and inhibits tumorgrowth. Nat Med 2002; 8: 1369–1375.
Luo Y, Zhou H, Mizutani M et al. Transcription factor Fos-relatedantigen 1 is an effective target for a breast cancer vaccine. ProcNatl Acad Sci U S A 2003; 100: 8850–8855.
Loeffler M, Kruger JA, Reisfeld RA. Immunostimulatory effects oflow-dose cyclophosphamide are controlled by inducible nitric oxidesynthase. Cancer Res 2005; 65: 5027–5030.
Kim TW, Hung CF, Ling M et al. Enhancing DNA vaccine potency bycoadministration of DNA encoding antiapoptotic proteins. J ClinInvest 2003; 112: 109–117.
Widera G, Austin M, Rabussay D et al. Increased DNA vaccine deliveryand immunogenicity by electroporation in vivo. J Immunol 2000; 164:4635–4640.
Hermans IF, Chong TW, Palmowski MJ et al. Synergistic effect ofmetronomic dosing of cyclophosphamide combined with specificantitumor immunotherapy in a murine melanoma model. Cancer Res 2003;63: 8408–8413.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer
About this chapter
Cite this chapter
Cohen, A.D., Wolchok, J.D. (2007). DNA Vaccines Against Cancer. In: Kaufman, H.L., Wolchok, J.D. (eds) General Principles of Tumor Immunotherapy. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6087-8_9
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6087-8_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6086-1
Online ISBN: 978-1-4020-6087-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)